ArticleCureus2025
Ameloblastic Fibrosarcoma Transformation From Recurrent Ameloblastic Fibroma: A Case Report From Morocco.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ameloblastic fibrosarcoma is an extremely rare odontogenic sarcoma, which consists of a benign epithelial and a malignant mesenchymal component. This rare tumor occurs de novo or from a pre-existing ameloblastic fibroma. We report a case of a 31-year-old male patient who developed a lung metastasis fibrosarcoma secondary to ameloblastic fibrosarcoma arising on a pre-existing mandibular ameloblastic fibroma. A thorough understanding of the radiological and histological aspects of mandibular tumors is essential to establish an accurate diagnosis and rule out other common benign and malignant odontogenic tumors that might display microscopic similarities. An appropriate management, including total surgical excision with safe margins, represents the preferred treatment of ameloblastic fibroma. Close monitoring is indicated to reduce the recurrence rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.